The journal of allergy and clinical immunology. In practice
-
J Allergy Clin Immunol Pract · Sep 2014
Randomized Controlled TrialExhaled breath condensate pH does not discriminate asymptomatic gastroesophageal reflux or the response to lansoprazole treatment in children with poorly controlled asthma.
Although exhaled breath condensate (EBC) pH has been identified as an "emerging" biomarker of interest for asthma clinical trials, the clinical determinants of EBC pH remain poorly understood. Other studies have associated acid reflux-induced respiratory symptoms, for example, cough, with transient acidification of EBC. ⋯ Despite the relative ease of EBC collection, EBC pH as a biomarker does not provide useful information of children with asthma who were enrolled in asthma clinical trials.
-
J Allergy Clin Immunol Pract · Sep 2014
Randomized Controlled Trial Multicenter StudyFluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial.
The inhaled corticosteroid fluticasone furoate (FF) in combination with the long-acting β2-agonist vilanterol (VI) is under development for the treatment of asthma and chronic obstructive pulmonary disease. ⋯ Significant improvement in lung function was observed with FF-VI and FF versus placebo in patients with persistent asthma. Improvement of FEV1 when VI was added to FF was not significant. The high placebo response in evening trough FEV1 may have influenced the assessment of efficacy.
-
J Allergy Clin Immunol Pract · Jul 2014
Randomized Controlled TrialReal-time asthma outreach reduces excessive short-acting β2-agonist use: a randomized study.
Excessive use of short-acting β2-agonists (SABA) indicates impaired asthma control. ⋯ A novel administrative-based asthma outreach program improves markers of asthma impairment in patients without prior asthma specialist care and is adaptable to managed care organizations with electronic medical records.
-
J Allergy Clin Immunol Pract · Nov 2013
Randomized Controlled Trial Multicenter StudyAnti-inflammatory treatment of atopic asthma guided by exhaled nitric oxide: a randomized, controlled trial.
Atopic asthma is characterized by Th2 cytokine-driven inflammation of the airway mucosa, which is signaled by the fraction of exhaled nitric oxide (FENO). ⋯ Use of FENO to guide anti-inflammatory treatment within primary care significantly reduced the exacerbation rate and improved asthma symptom control without increasing overall inhaled corticosteroid use.